BACKGROUND:Total mesorectal excision (TME) combined with preoperative short-term radiotherapy (PRT) reduces local recurrence rates in rectal cancer treatment. However, treatment with radiotherapy increased morbidity and did not result in a longer survival. The aim of this analysis is to provide a comprehensive longitudinal overview of the health-related quality of life (HRQL) and symptoms experienced by rectal cancer patients in the Dutch randomized TME trial from baseline until 14 years after treatment. METHODS:Rectal cancer patients (n =1530) were randomly allocated to PRT (5 × 5 Gy) followed by TME or to TME alone. At baseline, 3, 6, 12, 18, and 24 months, 5 years and 14 years after treatment HRQL was evaluated in surviving patients (n =606, at 14 years after treatment). RESULTS: None of the general symptoms differed significantly between PRT + TME and TME. However, in both treatment arms the general symptoms were increased at the diagnosis of rectal cancer, after surgery and by aging. With PRT + TME bowel symptoms were increased, specifically more fecal incontinence was reported at all time points, resulting in more use of pads for fecal incontinence (PRT + TME vs. TME at 5 years 51.5% vs. 30.5%, respectively, and at 14 years 56.4% vs. 37.1%, respectively). CONCLUSIONS: This longitudinal analysis shows that general symptoms in both groups are increased at the diagnosis of rectal cancer, after surgery and by aging, but not by RT. However, irradiated patients reported more bowel dysfunction at all time points.
RCT Entities:
BACKGROUND: Total mesorectal excision (TME) combined with preoperative short-term radiotherapy (PRT) reduces local recurrence rates in rectal cancer treatment. However, treatment with radiotherapy increased morbidity and did not result in a longer survival. The aim of this analysis is to provide a comprehensive longitudinal overview of the health-related quality of life (HRQL) and symptoms experienced by rectal cancerpatients in the Dutch randomized TME trial from baseline until 14 years after treatment. METHODS:Rectal cancerpatients (n =1530) were randomly allocated to PRT (5 × 5 Gy) followed by TME or to TME alone. At baseline, 3, 6, 12, 18, and 24 months, 5 years and 14 years after treatment HRQL was evaluated in surviving patients (n =606, at 14 years after treatment). RESULTS: None of the general symptoms differed significantly between PRT + TME and TME. However, in both treatment arms the general symptoms were increased at the diagnosis of rectal cancer, after surgery and by aging. With PRT + TME bowel symptoms were increased, specifically more fecal incontinence was reported at all time points, resulting in more use of pads for fecal incontinence (PRT + TME vs. TME at 5 years 51.5% vs. 30.5%, respectively, and at 14 years 56.4% vs. 37.1%, respectively). CONCLUSIONS: This longitudinal analysis shows that general symptoms in both groups are increased at the diagnosis of rectal cancer, after surgery and by aging, but not by RT. However, irradiated patients reported more bowel dysfunction at all time points.
Authors: Virginia Sun; Tracy E Crane; Samantha D Slack; Angela Yung; Sarah Wright; Stephen Sentovich; Kurt Melstrom; Marwan Fakih; Robert S Krouse; Cynthia A Thomson Journal: Contemp Clin Trials Date: 2018-03-19 Impact factor: 2.226
Authors: Patricio B Lynn; Lindsay A Renfro; Xiomara W Carrero; Qian Shi; Paul L Strombom; Oliver Chow; Julio Garcia-Aguilar Journal: Dis Colon Rectum Date: 2017-05 Impact factor: 4.585
Authors: Ebunoluwa E Otegbeye; Jonathan B Mitchem; Haeseong Park; Aadel A Chaudhuri; Hyun Kim; Matthew G Mutch; Matthew A Ciorba Journal: Transl Res Date: 2020-12-08 Impact factor: 7.012
Authors: Anouk J M Rombouts; Issam Al-Najami; Natalie L Abbott; Ane Appelt; Gunnar Baatrup; Simon Bach; Aneel Bhangu; Karen-Lise Garm Spindler; Richard Gray; Kelly Handley; Manjinder Kaur; Ellen Kerkhof; Camilla Jensenius Kronborg; Laura Magill; Corrie A M Marijnen; Iris D Nagtegaal; Lars Nyvang; Femke P Peters; Per Pfeiffer; Cornelis Punt; Philip Quirke; David Sebag-Montefiore; Mark Teo; Nick West; Johannes H W de Wilt Journal: BMJ Open Date: 2017-12-28 Impact factor: 2.692
Authors: Antoine Brouquet; Jean-Baptiste Bachet; Florence Huguet; Mehdi Karoui; Pascal Artru; Charles Sabbagh; Jérémie H Lefèvre; Dewi Vernerey; Christophe Mariette; Eric Vicaut; Stephane Benoist Journal: BMC Cancer Date: 2020-05-29 Impact factor: 4.430